Clinical Trial

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

Study acronym: YHAA
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-09-02; most recent amendment 2026-04-17.
Trial Details
NCT Number NCT07152002
Lead Sponsor Eli Lilly and Company
Conditions Overweight or Obesity, Healthy
Enrollment 144 participants
Start Date 2025-08-28
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-04-20